Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with chemotherapy +/- bevacizumab in resectable NSQ-NSCLC
NCT06775275Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Pathological Complete Response. Started Sep 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06775275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775275.